CG Oncology (NASDAQ:CGON) had its price target raised by analysts at Truist Financial Corporation from $66.00 to $75.00. They now have a "buy" rating on the stock.
CG Oncology (NASDAQ:CGON) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
CG Oncology (NASDAQ:CGON) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
CG Oncology: 'Strong Buy' On Earlier Than Expected Completed Recruitment Cretostimogene [Seeking Alpha]
CG Oncology (CGON) Is Up 29.7% After Accelerating PIVOT-006 Phase 3 Timeline - Has The Bull Case Changed? [Yahoo! Finance]